Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. HUTCHMED (China) Limited
  6. News
  7. Summary
    HCM   KYG4672N1198

HUTCHMED (CHINA) LIMITED

(HCM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hutchison China MediTech Launches Hong Kong IPO of 104 Million Ordinary Shares

06/18/2021 | 07:42am EDT


ę MT Newswires 2021
All news about HUTCHMED (CHINA) LIMITED
07/23HUTCHMED CHINA : Stabilizing Actions and End of Stabilization Period in connecti..
AQ
07/16HUTCHMED CHINA : Expands potential global reach of surufatinib, in addition to C..
PU
07/16HUTCHMED CHINA : European Regulator Accepts Hutchmed's Marketing Application for..
MT
07/16HUTCHMED CHINA : Cancer Drug Accepted For Review By European Medicines Agency
MT
07/16European Medicines Agency Accepts Marketing Authorization Application for Hut..
CI
07/15HUTCHMED CHINA : Marketing Authorization Application for Surufatinib Submitted a..
AQ
07/14TR-1 : Standard form for notification of major holdings (Form 6-K)
PU
07/13HUTCHMED CHINA : Earns $25 Million Milestone from AstraZeneca for First Commerci..
MT
07/13HUTCHMED CHINA : To Receive $25 Million From AstraZeneca On First Commercial Orp..
MT
07/13ASTRAZENECA : HUTCHMED Announces First Commercial Sale of ORPATHYS« in China, Tr..
AQ
More news
Financials (USD)
Sales 2021 342 M - -
Net income 2021 -217 M - -
Net cash 2021 224 M - -
P/E ratio 2021 -19,9x
Yield 2021 -
Capitalization 6 380 M 6 380 M -
EV / Sales 2021 18,0x
EV / Sales 2022 14,1x
Nbr of Employees 1 280
Free-Float 51,3%
Chart HUTCHMED (CHINA) LIMITED
Duration : Period :
HUTCHMED (China) Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HUTCHMED (CHINA) LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Last Close Price 7,45 $
Average target price 9,32 $
Spread / Average Target 25,0%
EPS Revisions
Managers and Directors
Christian Hogg Chief Executive Officer & Executive Director
Chig Fung Cheng Chief Financial Officer & Executive Director
Chi Keung To Executive Chairman
Wei Guo Su Executive Director & Chief Scientific Officer
Marek Kania Chief Medical Officer & Managing Director
Sector and Competitors
1st jan.Capi. (M$)
HUTCHMED (CHINA) LIMITED16.74%6 684
JOHNSON & JOHNSON9.21%452 602
ROCHE HOLDING AG11.50%327 852
PFIZER, INC.13.58%234 040
NOVARTIS AG-0.17%221 954
ELI LILLY AND COMPANY44.05%221 084